-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, there have been two major breakthroughs in the field of immunotherapy, namely PD-1/PD-L1 inhibitors and CAR-T cell therapy
.
Among them, the treatment of CAR-T cell therapy drugs is mainly to transfer CAR-T cells cultured in vitro to the human body.
By activating T cells to attack and kill tumor cells in the patient, it is a very effective immunotherapy method
.
Since cell gene therapy has great potential in cancer treatment, it is generally believed in the industry that the market prospect of CAR-T cell therapy will be very broad
.
Out of optimism about the market prospects, in China, many pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years
.
Incomplete statistics show that more than 20 domestic pharmaceutical companies have deployed CAR-T therapies, including Fosun Kate, WuXi Juno, Legend Bio, Keji Bio, Reindeer Medical, Sibiman Bio, Cinda Bio, etc.
.
In addition, in the near future, some companies have disclosed the company's new progress for CAR-T therapy
.
For example, on November 15th, Keji Pharmaceutical announced that its CT041 has been granted priority drug status (PRIME) by the European Medicines Agency (EMA) for the treatment of gastric cancer/gastroesophageal junction cancer
.
Keji Pharmaceutical pointed out that CT041 is an autologous CAR-T product candidate targeting CLDN18.
2.
It believes that CT041 is expected to become the backbone therapy in the treatment of gastric and pancreatic cancer worldwide
.
Under the background that domestic pharmaceutical companies are actively deploying CAR-T cell therapy drugs in the field, two domestic products have been approved for listing in China.
They are Akilunzai introduced by Fosun Kate and WuXi Juno in Juno in the United States.
Ricky Oren Race developed on the basis of JCAR017
.
However, it should be noted that due to the high cost of CAR-T cell therapy drugs, many patients’ families generally cannot afford the drugs
.
Therefore, the National Medical Insurance Bureau has been working hard in recent years to find ways to reduce the cost of CAR-T drugs and other oncology drugs
.
It is understood that in 2021, with the promotion of the fifth batch of centralized procurement and a new round of medical insurance negotiations, there have been good news of price reductions for many anti-tumor drugs.
.
For example, Bristol-Myers Squibb’s original drug paclitaxel injection 30mg specifications, listed on the Shandong medical insurance net price of 699.
8 yuan, but this time the National Medical Insurance Bureau gave a maximum price of only 168.
94 yuan; Eli Lilly’s original drug gemcitabine 0.
2 g specification, the net price is 340 yuan, and the maximum price this time is 135 yuan
.
It can be seen from the above that Guocai's efforts to adjust the price of anti-tumor drugs have become a great boon for the majority of cancer patients, and it is further helping patients to reduce the burden of drug costs
.
It is worth mentioning that recently there has been good news about the price cuts of oncology drugs
.
The Guangdong Pharmaceutical Trade Center released the information to be listed on the Internet on December 14.
The price of WuXi Juno's Ruiji Orense Injection (trade name: Benoda®) is 1.
29 million yuan per bottle
.
The drug was approved by the State Food and Drug Administration on September 3 this year.
It is the second approved CAR-T product in China and the first CAR-T product of China’s first category of biological products.
Relapsed or refractory large B-cell lymphoma (r/rLBCL) in adult patients after systemic treatment or above
.
In addition, Janssen’s oncology drug daratumumab injection is also included in the list of new drugs in the medical insurance catalog.
The annual cost of the product is as high as one million yuan; and before this round of medical insurance negotiations, daratumumab The injection has already been actively reduced in price
.
On the whole, the fifth batch of 7 anti-tumor drugs was adopted, and the average price was reduced by more than 50%
.
The industry believes that anti-tumor drugs are constantly facing the challenge of centralized procurement, and the price reduction of more CAR-T drugs in the future will also be very worth looking forward to
.
.
Among them, the treatment of CAR-T cell therapy drugs is mainly to transfer CAR-T cells cultured in vitro to the human body.
By activating T cells to attack and kill tumor cells in the patient, it is a very effective immunotherapy method
.
Since cell gene therapy has great potential in cancer treatment, it is generally believed in the industry that the market prospect of CAR-T cell therapy will be very broad
.
Out of optimism about the market prospects, in China, many pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years
.
Incomplete statistics show that more than 20 domestic pharmaceutical companies have deployed CAR-T therapies, including Fosun Kate, WuXi Juno, Legend Bio, Keji Bio, Reindeer Medical, Sibiman Bio, Cinda Bio, etc.
.
In addition, in the near future, some companies have disclosed the company's new progress for CAR-T therapy
.
For example, on November 15th, Keji Pharmaceutical announced that its CT041 has been granted priority drug status (PRIME) by the European Medicines Agency (EMA) for the treatment of gastric cancer/gastroesophageal junction cancer
.
Keji Pharmaceutical pointed out that CT041 is an autologous CAR-T product candidate targeting CLDN18.
2.
It believes that CT041 is expected to become the backbone therapy in the treatment of gastric and pancreatic cancer worldwide
.
Under the background that domestic pharmaceutical companies are actively deploying CAR-T cell therapy drugs in the field, two domestic products have been approved for listing in China.
They are Akilunzai introduced by Fosun Kate and WuXi Juno in Juno in the United States.
Ricky Oren Race developed on the basis of JCAR017
.
However, it should be noted that due to the high cost of CAR-T cell therapy drugs, many patients’ families generally cannot afford the drugs
.
Therefore, the National Medical Insurance Bureau has been working hard in recent years to find ways to reduce the cost of CAR-T drugs and other oncology drugs
.
It is understood that in 2021, with the promotion of the fifth batch of centralized procurement and a new round of medical insurance negotiations, there have been good news of price reductions for many anti-tumor drugs.
.
For example, Bristol-Myers Squibb’s original drug paclitaxel injection 30mg specifications, listed on the Shandong medical insurance net price of 699.
8 yuan, but this time the National Medical Insurance Bureau gave a maximum price of only 168.
94 yuan; Eli Lilly’s original drug gemcitabine 0.
2 g specification, the net price is 340 yuan, and the maximum price this time is 135 yuan
.
It can be seen from the above that Guocai's efforts to adjust the price of anti-tumor drugs have become a great boon for the majority of cancer patients, and it is further helping patients to reduce the burden of drug costs
.
It is worth mentioning that recently there has been good news about the price cuts of oncology drugs
.
The Guangdong Pharmaceutical Trade Center released the information to be listed on the Internet on December 14.
The price of WuXi Juno's Ruiji Orense Injection (trade name: Benoda®) is 1.
29 million yuan per bottle
.
The drug was approved by the State Food and Drug Administration on September 3 this year.
It is the second approved CAR-T product in China and the first CAR-T product of China’s first category of biological products.
Relapsed or refractory large B-cell lymphoma (r/rLBCL) in adult patients after systemic treatment or above
.
In addition, Janssen’s oncology drug daratumumab injection is also included in the list of new drugs in the medical insurance catalog.
The annual cost of the product is as high as one million yuan; and before this round of medical insurance negotiations, daratumumab The injection has already been actively reduced in price
.
On the whole, the fifth batch of 7 anti-tumor drugs was adopted, and the average price was reduced by more than 50%
.
The industry believes that anti-tumor drugs are constantly facing the challenge of centralized procurement, and the price reduction of more CAR-T drugs in the future will also be very worth looking forward to
.
